SEOUL-SEMICONDUCTOR
28.3.2024 14:01:29 CET | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), the world best-in-class technology in opto-semiconductors, is supplying and mass-producing “WICOP,” the world’s first high-power LEDs without wire, for the headlamps of Genesis GV80, a luxury SUV model by Hyundai Motor Group, which is one of the world’s top three automobile companies. The technology applies to all functions of the high-light, sophisticated headlamps introduced by GV80.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328561793/en/
Headlamps of GV80, a luxury SUV of Genesis, with Seoul Semiconductor’s WICOP technology applied (Photo: Seoul Semiconductor Co., Ltd.)
Seoul Semiconductor applied its new technology of Ultra-High Luminance “WICOP UHL” to the high and low beams of GV80, the two lines that symbolize Genesis vehicles. With its improved luminance by 200% compared to existing mass-produced WICOP products, WICOP UHL is attracting the attention of the automobile market as an optimized solution for slim lamp designs. In addition, WICOP was applied to all front-light functions of GV80, including the daytime running lights (DRL) and turn signal lights. This recognition is a testament of customer trust in the products of Seoul Semiconductor.
WICOP UHL, applied to the micro lens arrays (MLA) in the headlamps of Genesis, is a product optimized for automotive applications developed based on WICOP, an ultra-small, high-efficiency LED technology. Exhibiting up to 40% better heat dissipation performance than other LED products, it can reduce the size of the lamp heat-sink structure by up to 75%. As such, the technology allows the size and weight to be reduced, which are important factors in a lamp design, enabling an implementation of a slim and sophisticated design.
According to Genesis, “The adoption of Seoul Semiconductor’s technology has enhanced the completeness of the front face of GV80, our luxury SUV. In particular, the ability of WICOP UHL to emit a large amount of light through the small LED emitting area of about 0.5mm2 contributed to improving the visual quality in combination with the MLA technology. The expectation is that the technology will be applied to more models in the future.”
Vice President In-heum Park of the Automotive Division of Seoul Semiconductor stated, “The WICOP technology is the world’s first technology developed by Seoul Semiconductor and has been consistently adopted by car manufacturers around the world, being applied to more than 100 models every year. We will continue to develop automotive LED technologies to provide our customers with differentiated values.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240328561793/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 15:30:00 CEST | Press release
The collaboration expands FlexTrade’s front-office risk analytics offering, connecting portfolio construction, risk insight, and trading decisions in a unified buy-side workflow. FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and executio
Xsolla Connect Returns to Brighton13.7.2026 15:22:00 CEST | Press release
Connecting The UK Game Development Community For Networking And Insights During Develop:Brighton Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom